Image Name

Enterprise News

New Progress in Autoimmune Disease Pipeline! Vcare PharmaTech's VC005 Topical Gel Secures China IND Approval for Plaque Psoriasis

New Progress in Autoimmune Disease Pipeline! Vcare PharmaTech's VC005 Topical Gel Secures China IND Approval for Plaque Psoriasis

Recently, VC005 topical gel, a new-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), has officially obtained the IND approval from the CDE for the topical treatment of plaque psoriasis.

Time：2026-06-11 17:41

Vcare PharmaTech Enters into Exclusive Licensing Agreement with Everest Medicines for Sumecigrel Across Multiple Asia-Pacific Countries and Regions

Vcare PharmaTech Enters into Exclusive Licensing Agreement with Everest Medicines for Sumecigrel Across Multiple Asia-Pacific Countries and Regions

9 June 2026 – Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech，Company), a commercial-stage innovative biopharmaceutical firm leveraging AI for differentiated original drug design, today announced the signing of an exclusive licensing agreement with Everest Medicines (HKEX: 1952.HK). Under the deal, Vcare PharmaTech grants Everest Medicines exclusive rights for the clinical development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across multiple Asia-Pacific countries and regions (including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR and Taiwan region of China).

Time：2026-06-09 07:52

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib (VELMARTO®), has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

Time：2026-06-04 17:38

Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing

Capital Empowers Innovation: Vcare PharmaTech Completes Nearly RMB 200 Million Series C3 Financing

Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) has successfully closed its Series C3 financing totaling nearly RMB 200 million. The round was led by existing shareholder Hongcheng Investment, with follow-on investments from institutions including Xinghe Venture Capital, Hangzhou Jinlong, Hongyao Kechuang and Huadian Investment. Meanwhile, the firm has onboarded high-caliber new investors such as Huafuruixing, consolidating a solid capital foundation for its sustainable long-term growth.

Time：2026-06-02 17:36

The Fourth Self-Developed Innovative Drug Enters Pivotal Clinical Stage! Jiangsu Vcare’s VC005 Topical Gel Completes First Patient Enrollment in Phase III Clinical Trial

The Fourth Self-Developed Innovative Drug Enters Pivotal Clinical Stage! Jiangsu Vcare’s VC005 Topical Gel Completes First Patient Enrollment in Phase III Clinical Trial

Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced that VC005 Topical Gel, its self-developed second-generation highly selective JAK1 inhibitor, has completed the enrollment of the first patient in the phase III clinical trial for the treatment of mild-to-moderate atopic dermatitis (AD).

Time：2026-05-12 17:44

New Expansion in Topical Pipeline! Jiangsu Vcare’s VC005 Topical Gel Granted China IND Approval for New Indication of Vitiligo

New Expansion in Topical Pipeline! Jiangsu Vcare’s VC005 Topical Gel Granted China IND Approval for New Indication of Vitiligo

Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has officially obtained the IND approval from the CDE of the NMPA. The product is intended for the topical treatment of non-segmental vitiligo.

Time：2026-05-07 17:38

Significant Efficacy! Jiangsu Vcare’s VC005 Tablets Achieve Positive Topline Results in Phase III Clinical Trial for Moderate-to-Severe AD

Significant Efficacy! Jiangsu Vcare’s VC005 Tablets Achieve Positive Topline Results in Phase III Clinical Trial for Moderate-to-Severe AD

Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced a major milestone breakthrough in the Phase III clinical study of VC005 Tablets, its independently developed second-generation highly selective JAK1 inhibitor for the oral treatment of moderate-to-severe AD, achieved positive topline results for the primary endpoint. This key milestone marks a decisive step forward for VC005 Tablets toward market launch and provides new therapeutic hope for numerous patients with moderate-to-severe AD.

Time：2026-03-25 17:32

VC005 Topical Gel is to Launch Phase III Trials! Jiangsu Vcare’s Fourth Independently Developed Innovative Drug will enter the Confirmatory Clinical Stage

VC005 Topical Gel is to Launch Phase III Trials! Jiangsu Vcare’s Fourth Independently Developed Innovative Drug will enter the Confirmatory Clinical Stage

Recently, VC005 Topical Gel, a second-generation highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), has received ethical approval for its Phase III clinical trial. The Phase III study for the treatment of mild-to-moderate atopic dermatitis (AD) will soon be initiated, marking a pivotal milestone as this differentiated innovative topical drug advances into the confirmatory clinical stage.

Time：2026-03-06 18:02

< 1234...11 >
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

SEO

图片名称

苏公网安备32011202001742号

Powerby：www.300.cn nanjing.300.cn